Outlook Therapeutics, Inc.

What they do

Outlook Therapeutics developed ONS-5010/LYTENAVA as an ophthalmic formulation of bevacizumab for wet age-related macular degeneration. The product is approved in the EU, UK, and, since July 2026, the United States. The company launched directly in Germany and the UK in June 2025, expanded into Austria in 2026, and is building a U.S. commercial organization for a launch planned before the end of calendar 2026.

Revenue drivers

• LYTENAVA - Germany and UK — The company recognized $1.4 million of revenue in fiscal 2025 from shipments of LYTENAVA into Germany and the UK, the only product revenue reported to date.
• LYTENAVA - Austria — The company expanded into Austria in 2026, with launches in other European countries planned either directly or with a licensing partner.
• LYTENAVA - United States — Following FDA approval in July 2026, the company is preparing a U.S. launch before December 31, 2026, and states management believes LYTENAVA has potential to exceed $500 million in annual U.S. sales by 2030.
• Partner-led markets — In Switzerland, partner Mediconsult is leading regulatory and commercial activities for an anticipated 2027 launch; the Netherlands launch is planned for later in 2026.

Recent performance

For the third quarter of fiscal 2026, ended June 30, 2026, the company reported revenue of $1.5 million. Full fiscal 2025 revenue was $1.4 million from LYTENAVA shipments into Germany and the UK, against a fiscal 2025 net loss of $62.4 million. Cash and equivalents were $11.2 million at June 30, 2026, with total assets of $26.2 million, total liabilities of $36.6 million, and shareholder equity of negative $10.4 million. Operating cash flow was negative $51.8 million in fiscal 2025.

Strategy

The company's stated priority is preparing a U.S. commercial launch of LYTENAVA before the end of calendar 2026, including building a commercial team with retina and launch experience. It is expanding payer engagement, scaling commercial supply, and establishing customer segmentation targeting retina practices most likely to adopt early. The company plans to submit an application for a permanent HCPCS code by October 1, 2026 to support reimbursement. In Europe, it continues commercialization in Germany, Austria, and the UK while preparing launches in the Netherlands and Switzerland.

Risks

• Going concern and funding need — The 10-K states there is substantial doubt about the company's ability to continue as a going concern and that it will need to raise substantial additional funding.
• No material product revenue — Fiscal 2025 revenue was only $1.4 million and the company has not generated material revenue from product sales, with net losses of $62.4 million in fiscal 2025 and $75.4 million in fiscal 2024.
• Negative equity and liabilities above assets — At June 30, 2026, total liabilities of $36.6 million exceeded total assets of $26.2 million, leaving shareholder equity of negative $10.4 million.
• U.S. launch execution risk — The U.S. launch, planned before December 31, 2026, requires building a commercial organization, securing reimbursement, and competing in an evolving wet AMD and biosimilar landscape.

Outlook

Management expects to launch LYTENAVA in the United States before the end of calendar 2026 following July 2026 FDA approval, which provides 12 years of U.S. regulatory exclusivity. The company plans to submit for a permanent HCPCS code by October 1, 2026 to support reimbursement. In Europe, it plans a Netherlands launch later in 2026 and an anticipated Swiss launch in 2027 through partner Mediconsult. Management states LYTENAVA has the potential to exceed $500 million in annual U.S. sales by 2030.